Pdt Partners, LLC Aprea Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.62 - $1.94 $18,257 - $57,127	-29,447 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.59 - $3.16 $179,913 - $357,563	-113,153 Reduced 79.35%	29,447 $55,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $157,465 - $306,152	54,866 Added 62.54%	142,600 $409,000
Q3 2021 Nov 15, 2021	SELL	$3.43 - $5.63 $125,195 - $205,495	-36,500 Reduced 29.38%	87,734 $448,000
Q2 2021 Aug 16, 2021	BUY	$4.05 - $5.5 $503,147 - $683,287	124,234 New	124,234 $606,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,589
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.